Soft Tissue Sarcoma Market Report and Forecast 2025-2034

Soft Tissue Sarcoma Market Outlook

The soft tissue sarcoma market size is expected to grow at a CAGR of 5.5% during the forecast period of 2025-2034. The market is driven by the rising number of cancer patients and the growing demand for targeted therapies to treat soft tissue sarcoma across the 8 major markets.

Soft Tissue Sarcoma Market Overview

Soft tissue sarcoma is a cancer subtype that develops in soft tissues such as muscle, fat, tendons, and nerves. They represent 1% of all cancers that occur in adults . According to the American Cancer Society, 13,590 individuals will be diagnosed with soft tissue sarcoma in 2024, out of which 7,700 will be males and the rest 5,890 will be females. It is also predicted that it will cause mortality in 5,200 people.  The growing number of patients with this rare type of cancer is expected to fuel the soft tissue sarcoma market growth.

The emergence of novel therapies to treat soft tissue sarcoma is also aiding the market growth. In the 2023 American Society of Clinical Oncology Annual Meeting, it was revealed that the  combination of doxorubicin, balstilimab, and zalifrelimab demonstrated efficacy as well as favorable 6-month progression-free survival (PFS) rates in patients soft tissue sarcoma. The introduction of such treatment alternatives with manageable toxicity is anticipated to increase the soft tissue sarcoma market demand.

The market is projected to experience significant growth supported by the increasing adoption of targeted therapies along with the continued advancements in the drug pipelines throughout the forecast period. The rising healthcare expenditure and heightened patient awareness will also propel the market size.

Soft Tissue Sarcoma Market Trends

Soft Tissue Sarcoma Market Segmentation

Market Breakup by Treatment Type

• Radiation Therapy

• Anti-Angiogenesis

• Chemotherapy

• Targeted Therapy

• Others

Soft tissue sarcoma treatment includes radiation therapy, anti-angiogenesis agents, chemotherapy, targeted therapy, and other interventions. This segmentation outlines the range of therapeutic approaches employed to manage soft tissue sarcoma effectively with minimum adverse effects.

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Based on the route of administration, the soft tissue sarcoma market includes oral, parenteral, and others. In oral administration, medications are taken by mouth. Parenteral administration involves injections or infusions, to provide immediate therapeutic effect.

Market Breakup by End Users

• Hospitals

• Homecare

• Specialty Clinics

• Others

The market segmentation by end users comprises hospitals, homecare, and specialty clinics, among others. Hospitals act as the primary centres for the diagnosis and treatment of soft tissue sarcoma patients.

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online pharmacy

• Others

Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others. This distribution network enhances accessibility, catering to the diverse needs of the patients.

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain 
  • United Kingdom
• Japan

• India

The market segmentation on a regional basis offers insights into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America covers a significant portion of the market segment. This can be attributed to the rising prevalence of soft skin sarcoma and the growing demand for targeted therapies in the region.

Soft Tissue Sarcoma Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Endo International PLC

• Dr. Reddy's Laboratories Ltd

• Lupin

• Aurobindo Pharma

• Sun Pharmaceutical Industries Ltd.

• Merck & Co.

• Lilly

• Bayer AG

• Novartis AG

• GlaxoSmithKline PLC

• Pfizer Inc

• Sanofi

• Teva Pharmaceutical Industries Ltd.

• Mylan N.V.

• F. Hoffmann-La Roche Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Soft Tissue Sarcoma Market Report

• How has the soft tissue sarcoma market performed so far and how is it expected to evolve in the coming years?
• What are the major market trends influencing the market? 
• What are the market's major drivers, opportunities, and restraints? 
• What is the epidemiology and incidence of soft tissue sarcoma?
• How does the prevalence and incidence of soft tissue sarcoma affect the market landscape?
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited soft tissue sarcoma market growth during the forecast period? 
• What treatment type of soft tissue sarcoma will dominate the market share? 
• What are the prominent diagnostic methods and tools used in the detection and monitoring of soft tissue sarcoma?
• Which drugs are likely to arrive in the market during the forecast period?
• What key research initiatives are expected to boost the market value during the forecast period? 
• What are the factors driving regional disparities in soft tissue sarcoma treatment and outcomes?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?